Extract
Invasive pulmonary aspergillosis (IPA) is a potentially lethal opportunistic infection, mainly affecting immunocompromised patients, particularly those with prolonged neutropenia [1]. Several reports have shown thatAspergillusspp. can also cause IPA in patients witha prioriless severe immune dysfunction, such as those in intensive care units (ICUs) [2–5] or with chronic obstructive pulmonary disease (COPD) [5–8]. In these patients, diagnosis of IPA remains a challenge, because the reference diagnostic criteria (defined by the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG)) were developed for research in high-risk patients and not specifically for patients in the ICU or patients with COPD [9]. Two alternative algorithms have been proposed for this setting: the COPD algorithm for patients with COPD [6] and the Clinical algorithm for patients in the ICU [10].
Abstract
In ICU COPD patients, the Clinical algorithm seems to be more useful to diagnose IPA than the COPD or EORTC/MSG oneshttp://ow.ly/N2TN30e6Zur
Acknowledgements
AspICU研究调查人员如下:米格uel Blasco-Navalpotro, Hospital Universitario Severo Ochoa (Madrid, Spain); Stijn Blot, Ghent University (Ghent, Belgium); Nele Brusselaers, Ghent University Hospital, (Ghent, Belgium); Pierre Bulpa, Mont-Godinne University Hospital (Yvoir, Belgium); Teresa Cardoso, Hospital de Santo Antonio (Porto, Portugal); Pierre-Emmanuel Charles, Dijon University Hospital (Dijon, France); Didier Clause, Cliniques de l'Europe (Brussels, Belgium); Patricia Courouble, Cliniques Universitaires Saint Luc (Brussels, Belgium); Emmanuel De Laere, Heilig Hartziekenhuis Roeselaere-Menen (Roeselaere, Belgium); George Dimopoulos, University Hospital Attikon (Athens, Greece); Frédéric Forêt, Centre Hospitalier Régional Mons-Warquignies (Mons, Belgium); Dan Li, Shangai Public Health Clinical Center (Shangai, China); Claude Martin, Assistance publique hôpitaux de Marseille, (Marseille, France); Shahram Mashayekhi, Centre Hospitalier Grand Hornu (Hornu, Belgium); Wouter Meersseman, Universitair Ziekenhuis Gasthuisberg (Leuven, Belgium); Benoit Misset, Hôpital Saint-Joseph (Paris, France); José Artur Paiva, Hospital de Sao Joao, (Porto, Portugal); Paulo Mergulhao, Hospital de Sao Joao (Porto, Portugal); Alessandro Pasqualotto, Santa Casa-Complexo Hospitalar (Porto Allegre, Brazil); Marcos Pérez, Vall d'Hebron University Hospital (Barcelona, Spain); Ratna Rao, Apollo Hospital (Hyderabad, India); Jordi Rello, Joan XXIII University Hospital (Tarragona, Spain) and Vall d'Hebron University Hospital (Barcelona, Spain); Jessica Souto, Vall d'Hebron University Hospital (Barcelona, Spain); Herbert Spapen, Brussels University Hospital (Brussels, Belgium); Fabio Silvio Taccone, Hôpital Erasme (Brussels, Belgium); Anne-Marie Van den Abeele, AZ Sint Lucas, (Ghent, Belgium); Koenraad Vandewoude, Ghent University Hospital, (Ghent, Belgium); and Dirk Vogelaers, Ghent University Hospital (Ghent, Belgium).
Footnotes
Support statement: This study received an unrestricted educational grant from Pfizer Belgium and a research grant from Ghent University. S. Blot holds a research mandate from Ghent University. The AspICU project was endorsed by the European Critical Care Research Network of the European Society of Intensive Care Medicine. The funding bodies had no role in collecting, analysing or interpreting the data, and were not involved in the writing or approval of the final manuscript. Funding information for this article has been deposited with theCrossref Funder Registry.
Conflict of interest: Disclosures can be found alongside this article atwww.qdcxjkg.com
- ReceivedSeptember 20, 2016.
- AcceptedJune 22, 2017.
- Copyright ©ERS 2017